Ultimate magazine theme for WordPress.

BTC
$8,093.65
+1.38%
ETH
$257.07
+2.33%
LTC
$103.66
+6.5%
DASH
$158.55
+0.11%
XMR
$87.48
+1.71%
NXT
$0.03
0%
ETC
$7.37
+1.94%
DOGE
$0.00
+1.2%
ZEC
$73.81
-0.39%
BTS
$0.07
0%
DGB
$0.02
+3.41%
XRP
$0.39
+1.4%
BTCD
$20.33
PPC
$0.41
0%
CRAIG
$0.00
XBS
$2.00
XPY
$0.01
0%
PRC
$0.00
0%
YBC
$1,439.57
0%
DANK
$0.00

Merck Raises Full Year Guidance

145

Merck (MRK) raised its full-year guidance on Tuesday as the drugmaker posted better-than-expected results for its fiscal first quarter which were supported by rising sales of pharmaceuticals. The Kenilworth, N.J.-headquartered company reported revenue of $10.82 billion, up 8% from $10.04 billion in the corresponding quarter of last year. This was ahead of the consensus estimate of analysts polled by Capital IQ for $10.45 billion.

- Advertisement -

Just-released report names Cannabis Stock of the Year for 2019! Their last pick has seen a +1,200% return since he released it!

This stock has all of the makings of the next great cannabis stock – early-mover advantage, international exposure and influential partnerships, plus it has a product that is unlike anything else on the market…

You will also receive a free, weekly newsletter to stay on top of the latest industry trends, read analysis on promising cannabis stocks, and more. Click here to receive your Free Report immediately!

The result was buoyed by an 8% increase in revenue from pharmaceutical to $9.66 billion. The increase was driven primarily by growth in oncology and vaccines, partially offset by the ongoing impacts of the loss of market exclusivity for several products.

Comments